October 02, 2014
The plaintiffs in an upcoming pay-for-delay trial in multidistrict litigation against AstraZeneca PLC and others over Nexium fired back Thursday against a Covington & Burling LLP attorney's attempt to avoid testifying via live video feed, saying he offered "no legitimate grounds" to quash the subpoena.
September 29, 2014
AstraZeneca PLC and two generic drugmakers on Monday pushed a Massachusetts federal court to block two pharmaceutical industry experts from testifying at an upcoming pay-for-delay antitrust class action trial over heartburn drug Nexium, accusing the plaintiffs of trying to rehash discredited arguments.
September 25, 2014
A Massachusetts federal judge on Thursday refused to bar two experts from testifying at an upcoming pay-for-delay antitrust class action trial in multidistrict litigation against AstraZeneca PLC and Teva Pharmaceutical Industries Ltd. over the heartburn drug Nexium, after the parties argued about the reliability of the experts' opinions.
September 24, 2014
Plaintiffs in an upcoming pay-for-delay trial in multidistrict litigation against AstraZeneca PLC and Teva Pharmaceutical Industries Ltd. over the heartburn drug Nexium on Tuesday shot back at the companies' attempt to exclude expert testimony, saying the experts' opinions are comprehensive and reliable.
September 22, 2014
A Covington & Burling LLP attorney blasted a bid by plaintiffs in an upcoming pay-for-delay trial in multidistrict litigation against AstraZeneca PLC and others over the heartburn drug Nexium to force him to offer live testimony via video feed, saying that a prerecorded deposition should suffice.
September 15, 2014
Drugmakers Teva Pharmaceutical Industries Ltd. and AstraZeneca PLC on Friday asked a Massachusetts federal judge to bar a pharmaceutical expert from testifying at an upcoming pay-for-delay antitrust class action trial over Nexium, saying the witness' calculation of reasonable royalty rates was unreliable.
September 03, 2014
Generic-drug maker Ranbaxy Inc. on Tuesday told a Massachusetts federal court it did not need to turn over additional documents ahead of a trial in a pay-for-delay multidistrict litigation involving the heartburn drug Nexium, saying direct-purchaser plaintiffs' supplement production request ignores recent court decisions and federal rules.
August 26, 2014
Drugmakers Teva Pharmaceutical Industries Ltd. and AstraZeneca PLC on Monday asked a Massachusetts federal judge to toss claims that Teva purposely delayed marketing a generic version of Nexium by two years, saying the judge's recent rulings blow a hole in a class of drug buyers' antitrust suit against the companies.
August 20, 2014
Direct-purchaser plaintiffs in the pay-for-delay multidistrict litigation involving the heartburn drug Nexium on Tuesday asked a Massachusetts federal judge to compel generic-drug maker Ranbaxy Inc. to carry out supplemental production of documents ahead of an October trial, saying that the request is not burdensome.
March 21, 2014
Teva Pharmaceutical Industries Ltd. on Thursday urged a Massachusetts federal judge to uphold its win in a pay-for-delay class action involving the heartburn drug Nexium, asserting that the direct purchaser class plaintiffs' expert witness had not presented any solid evidence of illicit payment or reasonable damages.